Teva Pharmaceutical Industries Ltd. ADR 1.27% $18.72B ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

GSK (GSK) announced that the European Commission, EC, has approved a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease, IMD, caused by ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

The GlaxoSmithKline Capital PLC-Bond has a maturity date of 4/10/2042 and offers a coupon of 5.2500%. The payment of the coupon will take place 1.0 times per Year on the 10.04.. The ...

(Alliance News) - GSK PLC on Wednesday said its meningitis vaccine, Menveo, has received approval from the European Commission in a new single-vial, fully liquid presentation. In 2022, the ...

(Alliance News) - GSK PLC on Wednesday said its meningitis vaccine, Menveo, has received approval from the European Commission in a new single-vial, fully liquid presentation. In 2022, the London ...

incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 41,409.61 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.